Clinical findings and viremia for NHPs challenged with BEBOV.

98C007 expired before sampling at day 10 could be achieved.
a rVSV blend; rVSV-SEBOV-GP plus rVSV-ZEBOV-GP, rVSV Prime-boost; rVSV-SEBOV-GP first then rVSV-ZEBOV-GP 14 days after.
°F over baseline or at least 1.5°F over baseline and ≥103.5°F. Moderate rash refers to petechiae coverage of more than 20% of the skin. Lymphopenia and thrombocytopenia are defined by a ≥35% drop in numbers of lymphocytes and platelets, respectively. (ALP) alkaline phosphatase, (AST) aspartate aminotransferase, (BUN) blood urea nitrogen, (GGT) gamma glutamyltransferase: 2- to 3-fold increase,→; 4- to 5-fold increase, →→; >5 fold increase, →→→.b Days after BEBOV challenge are in parentheses. Fever is defined as a temperature more than 2.5
c No symptoms observed.
10 PFU/ml/qRT-PCR positive (+) or negative (−). +, ≤5 log10; ++, ≥6 log10; +++, ≥7 log10.d Days after BEBOV challenge are in parentheses. Viral load for each day is depicted as: log